Nanvuranlat

Phase 3Small molecule

JJ-Pharma Co., Ltd.

Nanvuranlat is one of 3 small molecule programs targeting Advanced Biliary Tract Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Biliary Tract CancerRecruiting

Advanced Biliary Tract CancerPhase 3

Recruiting

Competition

Competitive Landscape

4 competitors in Advanced Biliary Tract Cancer

#DrugCompanyPhaseTrials

Lenvima

Eisai

Phase 2

1 2

Mfolfox6

Roche

Phase 2

1 3

Nanvuranlat

JJ-Pharma Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Advanced Biliary Tract Cancer

NCT07265674

Clinical

Trials by Indication[1]

Advanced Biliary Tract Cancer1 trial

A Phase 3, Multicenter, Randomized, Open-label, Study Evaluating the Efficacy and Safety of Nanvuranlat in Patients With Previously Treated Advanced Biliary Tract Cancer

Recruiting·JJ-Pharma Co., Ltd.·Phase 3·NCT07265674·480 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nanvuranlat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nanvuranlat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nanvuranlat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — J-Pharma Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJ-Pharma Co., Ltd.

Nanvuranlat

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Advanced Biliary Tract Cancer1 trial

References

Drug Info

Quick Facts

Related News